Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh
Hussain et al., International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020 (Preprint)
Hussain et al., Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh, International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020 (Preprint)
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.
Hussain et al., 11 Dec 2020, preprint, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/346639384 Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh Article in International Journal of Molecular and Immuno Oncology · December 2020 DOI: 10.25259/IJMIO_30_2020 CITATIONS READS 2 1,787 3 authors, including: s.M Hussain Md Shuayb Square Hospitals Limited Vancouver General Hospital 2 PUBLICATIONS 6 CITATIONS 20 PUBLICATIONS 20 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Chemotherapy View project Head and Neck Cancer View project All content following this page was uploaded by Md Shuayb on 04 December 2020. The user has requested enhancement of the SEE PROFILE www.ijmio.com International Journal of Molecular & Immuno Oncology Article in Press Short Communication Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh Syed Md Akram Hussain1, Md Shuayb2, Mahmudur Rahman3 Department of Oncology, Square Hospitals, West Panthapath, Dhaka, Bangladesh, 2Vancouver Prostate Centre, Vancouver General Hospital, The University of British Columbia, Vancouver, Canada, 3Emerging Infections Program, IDD, International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh. 1 *Corresponding author: Syed Md Akram Hussain, Department of Oncology, Square Hospitals, West Panthapath, Dhaka, Bangladesh. syedmdakram@gmail.com Received : 17 September 2020 Accepted : 20 October 2020 Published : DOI: 10.25259/IJMIO_30_2020 Quick Response Code: The world, today, is facing an immense challenge with the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection known as coronavirus disease 2019 (COVID-19). Bangladesh is the 16th ranked pandemic part of the world with 244,020 cases diagnosed and 3234 deaths to date.[1] At present, no FDA approved remedies are available to defeat this deadly disease. Ivermectin, an antiparasitic drug, has been found to inhibit the replication of the SARS-CoV-2 virus in vitro.[2] When combined with doxycycline, an antibacterial drug, ivermectin showed encouraging activity in reducing viral load, possible molecular mechanisms of which have been proposed very recently.[3,4] Globally, a number of clinical trials are going on to explore the activity of these two widely used FDA approved drugs as a potential therapy for SARS-CoV-2 infection. Although no systematic data are available, several studies including the European Society for Medical Oncology and the National Institute for Health and Care Excellence guidelines have reported that cancer patients are more vulnerable to develop COVID-19 infection.[5] We sought to investigate the effectiveness of ivermectin plus doxycycline in COVID-19-positive cancer patients in a tertiary care cancer center of Dhaka city in Bangladesh. This is a case series conducted at the Oncology and Radiotherapy Centre of Square Hospital, Bangladesh. A total of eight patients were treated with ivermectin and doxycycline combination to date, who met the eligibility criteria. The primary outcome was treatment response and the secondary outcome was treatment-related toxicity. Inclusion criteria included in this study were patients with any stage of solid malignancies or lymphoma proved by pathology; active disease being treated with chemotherapy and/or..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit